D-0599-2024 Class III Ongoing

Recalled by Rising Pharma Holding, Inc. — East Brunswick, NJ

FDA drug recall D-0599-2024 was initiated by Rising Pharma Holding, Inc. on Jun 24, 2024 and is designated Class III. Reason for recall: Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit. The recall status is ongoing. Affected quantity: 868 tubes.

Recall details

Product Type
Drugs
Report Date
Jul 17, 2024
Initiation Date
Jun 24, 2024
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
868 tubes

Product description

Diflorasone Diacetate Ointment, USP, 0.05%, 60g tube, Rx only, Mfd. By: Lyne Laboratories, Inc., Brockton, MA 02301; Mfd. For: Rising Pharmaceuticals, Inc., East Brunswick, NJ 08816 NDC 64980-124-60

Reason for recall

Failed Impurities/Degradation Specifications: The impurity results at 12 months stability testing,did not conform to the specification limit.

Distribution pattern

Nationwide in the USA

Code information

Lot #, DI2303B, Exp 12/31/2024

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0599-2024
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0599-2024. Report a data issue: hello@regdatalab.com.